Julie Vose, MD, MBA, Professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, College of Medicine, takes a deep dive into the various treatment options available for chronic lymphocytic leukemia, including an update on novel therapies for indolent non-Hodgkin lymphoma and treatment sequencing for aggressive non-Hodgkin lymphoma. 

This educational activity will award continuing education hours for physicians and nurses.

Learning Objectives: 
At the end of this educational activity, participants should be able to: 

- Describe the latest recommendations for diagnosing, treating, and monitoring non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.   

- Identify emerging strategies for improving the quality of symptom management and survivorship care for patients with non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.  

-Evaluate tools and resources for managing non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia that can be used to achieve effective care and improve the patient experience.  

- Apply new knowledge to improve the delivery of effective and appropriate care to patients with non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.

10.02.20 Overview

Learn about the recent developments and current treatment algorithms for hepatocellular carcinoma, and understand the recent advances in pancreatic cancer and systemic therapy for biliary tract cancers.

Learning Objectives

At the end of this educational activity, participants should be able to:

1.       Describe the latest recommendations for diagnosing, treating, and monitoring hepatobiliary, pancreatic, and gastroesophageal cancers.   

2.       Identify emerging strategies for improving the quality of symptom management and survivorship care for patients with hepatobiliary, pancreatic, and gastroesophageal cancers.  

3.       Evaluate tools and resources for managing hepatobiliary, pancreatic, and gastroesophageal cancers that can be used to achieve effective care and improve the patient experience.   

4.       Apply new knowledge to improve the delivery of effective and appropriate care to patients with hepatobiliary, pancreatic, and gastroesophageal cancers. 

10.16.20 Overview

On January 1, 2021, big transformations to the office and outpatient evaluation and management (E&M) services (CPT® codes 99202-99215) will take place. Come away with essential information and applicable strategies to strengthen your cancer program’s operations and prepare for these changes.

Learning Objectives: 

At the end of this educational activity, participants should be able to: 

1.Summarize the Evaluation and Management code changes for 2021. 

 2.Identify strategies for selecting the appropriate E/M codes based on the new criteria. 

 3.Identify steps to prepare a practice for the transition. 

10/30/20 (NO CE) 

Overview: Find out how policy changes and new legislation will shape care delivery on both a local and national level.  



Elizabeth Plimack, MD, MS Chief, Division of Genitourinary Medical Oncology Professor, Department of Hematology/Oncology Fox Chase Cancer Center, Temple University

(Moderator) Ian Okazaki, MD  

Board Member, HSCO Medical Oncologist Straub Clinic and Hospital   


Carey Anders, MD  Medical Oncologist  Duke Cancer Center 


Julie Vose, MD, MBA  Professor, Internal Medicine  Division of Oncology & Hematology  University of Nebraska Medical Center, College of Medicine


William Harris, MD  Associate Professor, Division of Oncology  University of Washington School of Medicine; Seattle Cancer Care Alliance


Allison M. Hirschorn  Senior Coding and Reimbursement Specialist, Clinical Affairs 

American Society of Clinical Oncology 


Blake Oshiro Executive Vice President, Public Policy Capitol Consultants of Hawaii Teri Bedard, RT(R)(T), CPC Executive Director, Client & Corporate Resources Revenue Cycle Coding Strategies Christian G. Downs, JD, MHA Executive Director Association of Community Cancer Centers


Accreditation Statement



In support of improving patient care, these activities have been planned and implemented by AXIS Medical Education and Hawaii Society of Clinical Oncology (HSCO).  AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.




These activities were planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit each for learning and change.


Credit Designation for Physicians AXIS Medical Education designates these live activities for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ each. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Credit Designation for Nursing AXIS Medical Education designates these continuing nursing education activities for 1.0 contact hour each. 

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

AXIS Contact Information For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.  

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: 


Name of Faculty or Presenter/Planner

Reported Financial Relationship



Carey Anders, MD

Research Funding: G1-Therapeutics, Lilly, Merck, Nektar, PUMA, Seattle Genetics, Tesaro Consulting: AstraZeneca, Eisai, Genentech, IPSEN, Novartis, Seattle Genetics Honorarium: UpToDate and Jones & Bartlett

William Harris, MD

Advisor: Eisai, Zymeworks  Contracted Research: Agios, BMS, BTG, Basilea, Bayer, ExelixisMedimmune, Merck 

Allison M. Hirschorn 

Nothing to disclose

Ian Okazaki, MD

Nothing to disclose

Elizabeth Plimack, MD, MS

Research Grant: Astellas, BMS, Genentech, Merck

Scientific Advisory: AstraZeneca, Genentech, Infinity Pharma, Merck, Pfizer, Seattle Genetics

Sponsored and Non-Sponsored CME Programs: ASCO GU, Clinical Care Options Fox Chase Cancer Center, Mt. Sinai Icahn School of Medicine, Medscape, NCCN, OncLive, PER, Research to Practice, Spire Learning, University of Pennsylvania, Thomas Jefferson Kimmel Cancer Center

Julie Vose, MD, MBA

Advisor Abbvie, Epizyme, Legend Pharmaceuticals, Vaniam Group, Janssen/Pharmacyclics, Kite Pharma, Acerta/Astra-ZenecaVerastemMiltenyl Biotec Inc, Loxo Oncology, AllogeneWugene, Celgene  Research Grant: Acerta/Astra-Zeneca, Celgene, Incyte Corp, Kite Pharma, Novartis, Seattle Genetics, Inc.  




The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:


Name of Planner/Manager/Reviewer

Reported Financial Relationship



Michael Carney

Nothing to disclose

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Christy Levine

Nothing to disclose

Charles Miller, MD

Nothing to disclose

Dee Morgillo, MEd., MT (ASCP) CHCP

Nothing to disclose

Ryon Nakasome, MD

Nothing to disclose



Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

§  Attend/participate in the educational activity and review all course materials.

§  Complete the CE Declaration form online by 11:59 PM ET within 14 days of the conclusion of each activity. Instructions will be provided during the activity.  

§  Upon successful completion of the online form, your statement of completion will be presented to you to print.



Julie Vose, MD, MBA

University of Nebraska Medical Center/College of Medicine

Ryon Nakasone, MD (Moderator)

Medical Oncologist, Hawaii Oncology

Ryon K. Nakasone, MD, is a medical oncologist affiliated with the MD Anderson Cancer Network in Hawaii, largely practicing at the Kapiolani Medical Center for Women & Children, Kuakini Health System, and The Queen's Medical Center.



The Hawaii Society of Clinical Oncology (HSCO) is a Chapter Member of the Association of Community Cancer Centers (ACCC). HSCO members receive access to valuable educational content and targeted resources through ACCC to support their professional development.

· The ACCC COVID-19 Resource Center contains webcasts, podcasts, and blogs, and resources on the pandemic from federal and professional organizations.

· The ACCC COVID-19 Financial Advocacy Resources Hub features new and updated foundation assistance, updates to manufacturer assistance programs, and Medicare and Medicaid coverage updates.

· HSCO members can connect in real-time through members-only virtual discussion forum on ACCCeXchange. Within this forum, HSCO members from every profession involved in cancer care delivery ask and answer questions, discuss common challenges, and share knowledge and experience.  Join the discussion and connect with your peers.

·  Tap into the value of HSCO membership! Visit our membership page for more information on how you can join our community of professionals. If you’re unsure of your membership status, please contact our membership department today.

·  Project ECHO: Advances in Multiple Myeloma and Acute Lymphoblastic Leukemia – Through a partnership with the American Cancer Society and Project ECHO, ACCC is offering case-based didactic presentations by experts to improve content knowledge and share evidence-based best practices. 

·  The ACCC Multidisciplinary Acute Lymphocytic Leukemia (ALL) Care education project identifies key barriers to—and opportunities for improving the cancer care team’s support of patients diagnosed with ALL.

 · The ACCC Multidisciplinary Chronic Lymphocytic Leukemia (CLL) Care education project seeks to understand the current landscape of treating CLL in the community, identify effective practices and potential gaps in communications, and provide peer-to-peer resources.

· The ACCCeLearning portal makes it easy to find education relevant to your needs and interests. Accessible on any device and at any time, courses are available in a variety of formats, so you can listen, watch, read or interact in ways that best suit your needs. Health professionals can claim CME/CPE/CNE credit for all applicable activities. Since you’re already logged in, take a look around today!



Webinar 3: HSCO Clinical Education Series
09/25/2020 at 2:00 PM (EDT)   |  60 minutes
09/25/2020 at 2:00 PM (EDT)   |  60 minutes
HSCO Webinar: Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Chronic Lymphocytic Leukemia Feedback Survey
16 Questions
Up to 1.00 medical credits available  |  Certificate available
Up to 1.00 medical credits available  |  Certificate available

Already registered?
Log in to access.

Log In